Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FHND1002 in ALS
NCT07138014Phase 2Not yet recruiting
- Sponsor
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of FHND1002 in amyotrophic lateral sclerosis (ALS), sponsored by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
FHND1002
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07138014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07138014.